Abeona Therapeutics Inc. (LON:0H7R)
London
· Delayed Price · Currency is GBP · Price in USD 5.99
-0.20 (-3.22%)
At close: Jun 16, 2025
Abeona Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
227.83M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Indivior | 905.57M |
Abeona Therapeutics News
- 13 days ago - Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
- 16 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - Seeking Alpha
- 4 weeks ago - Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Abeona Therapeutics GAAP EPS of -$0.24 beats by $0.12 - Seeking Alpha
- 4 weeks ago - Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 5 weeks ago - UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder - GlobeNewsWire